A bold, central claim: combining stem cell therapy with BDNF enhancement could redefine how Parkinson’s disease is treated, offering both immediate relief from symptoms and longer-term disease modification.
Parkinson’s disease (PD) is a progressive, age-related neurodegenerative disorder characterized by the loss of dopamine-producing neurons. To address the limitations of traditional levodopa-centered treatment, researchers are increasingly turning to advanced, multi-modal strategies. A recent review highlights the potential of pairing stem cell therapy with brain-derived neurotrophic factor (BDNF) enhancement as a synergistic approach that may deliver both symptomatic improvement and disease modification.
PD primarily affects older adults and stems from the accumulation of pathogenic proteins alongside degeneration of nigrostriatal dopaminergic neurons in the substantia nigra. Clinically, PD presents with motor symptoms such as tremor, slowness of movement (bradykinesia), rigidity, and postural instability, and it can also involve a range of non-motor symptoms. Global data show a rising incidence of PD worldwide, underscoring the need for treatments that alleviate both motor and non-motor manifestations while slowing disease progression.
The standard treatment uses levodopa, a dopamine precursor, which can effectively reduce motor symptoms initially but tends to lose efficacy over time and carries risks of psychiatric side effects and motor complications. While deep brain stimulation and continuous infusion therapies offer alternative options, they come with high costs and potential adverse effects. These realities highlight the demand for safer, more effective therapeutic approaches.
Combination therapies—those that integrate multiple treatment modalities—often outperform single-therapy regimens. Recent work has explored stem cell–based interventions for PD, alongside brain-derived neurotrophic factors that support neuron growth, survival, and function. A new review led by Dr. Jonny Jonny from Indonesia Defense University investigates whether a dual strategy—BDNF with stem cell therapy—can promote neuroregeneration and functional recovery in PD. Dr. Jonny described the motivation behind the study:
"We wanted to explore if combining BDNF with stem cell therapy can promote neuroregeneration and functional recovery in PD." The study appears in volume 11 of the Chinese Neurosurgical Journal in November 2025.
In stem cell transplantation, the aim is to replenish lost dopaminergic neurons by introducing progenitor cells. Induced pluripotent stem cells (iPSCs) are particularly attractive because they are genetically matched to the donor, reducing immune rejection risk. Nonetheless, stem cell therapies face challenges, including inconsistent differentiation outcomes and the potential for tumor formation. Dr. Jonny cautions that further optimization is needed to ensure safety and effectiveness for PD.
BDNF upregulation has shown in animal models to reduce neuronal loss and improve motor function. BDNF interacts with the TrkB receptor and activates pathways that inhibit cell death, promote synaptic plasticity, and modulate inflammation. Delivering BDNF to the brain remains problematic, however, because the molecule does not readily cross the blood–brain barrier and can cause unwanted systemic or local side effects.
Given these challenges, researchers are pursuing a combined approach. In this strategy, stem cells are genetically engineered to continuously produce and secrete BDNF after transplantation. Early studies indicate that BDNF-modified stem cells differentiate more effectively into dopaminergic-like neurons and express transcription factors that enhance dopamine release. The presence of BDNF also appears to boost neuronal survival by upregulating anti-apoptotic proteins and dampening pro-apoptotic signals. Moreover, the dual approach may help control neuroinflammation by reducing proinflammatory cytokine expression. In rat models, this combination has been associated with higher dopamine levels and better behavioral outcomes.
If this dual therapy can be translated into clinical practice, it could satisfy both symptomatic relief and disease-modifying goals for PD. While challenges remain, advances in cellular engineering, delivery methods, and safety controls hold promise for broader adoption. Dr. Jonny remarks, "If this dual treatment strategy is successfully translated, it can change the way Parkinson's disease is treated. It will help in long-term symptom relief and even alter the disease trajectory."
Source:
Jonny, J., et al. (2025). Synergy between stem cell therapy and brain-derived neurotrophic factor (BDNF) in Parkinson’s disease: a mini-review of combined neuroregenerative strategies. Chinese Neurosurgical Journal. DOI: 10.1186/s41016-025-00415-5.
Note: This content summarizes a scientific review and does not constitute medical advice. Always consult a healthcare professional for medical guidance. For the most reliable information, refer to the original journal publication and reputable medical sources.
